No Prescription |
 |
 | ||
|
Newven OD Pristiq |
|
| ||
No Prescription » Prescription Drugs 11 » Newven OD Pristiq Desvenlafaxine is an antidepressant (serotonin-norepinephrine reuptake inhibitor type-SNRI) used in the treatment of depression. It works by restoring the balance of natural substances (neurotransmitters such as serotonin and norepinephrine) in the brain. Desvenlafaxine may improve your mood feelings of well-being and energy level. Buy Newven OD Pristiq and other Prescription Drugs 11 products online at Medstore. Buy Online at Medstore - Click Here!
About Newven OD Pristiq: Product Type: Prescription Drugs 11 Newven OD (Pristiq Generic Desvenlafaxine) Newven OD (Pristiq Generic Desvenlafaxine) Pristiq Generic Desvenlafaxine 100mg 100 Tablets 100mg 200(2 x 100 Tablets) 100mg 400(4 x 100 Tablets) 50mg 100 Tablets 50mg 200(2 x 100 Tablets) 50mg 400(4 x 100 Tablets) Pristiq Generic Desvenlafaxine Newven OD
View more Prescription Drugs 11 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
